Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Xbrane Biopharma, Webcast, Q1'26

By Inderes5/5/2026, 7:00 AM
Xbrane Biopharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin
00:02 - 12:29

Hello, everybody. My name is Martin. I'm the CEO of Xbrane, and I'm here together with Jane, our CFO. We will go through the highlights of our Q1 report 2026. I will start with an operational update, and Jane will thereafter go through the financials. So we will start with Ximluci, our Lucentis biosimilar. And we will then go through some highlights in relation to Xdivane, our Opdivo biosimilar candidate. On the development, Ximluci has been launched across 24 countries in Europe and the Middle East, and it's a product which we have partnered with. STADA is commercializing the product across these different countries, and it's a quite simple setup where we share the profit contribution, post-production costs and sales and marketing expenses. 5050. And it's a sizable addressable market. If we look at it as anti-VEGF products for retinal disorders. We have, of course, then Lucentis and the Lucentis biosimilars. That's the dark blue chunk in the bottom of this graph on the left-hand side. Active ingredient ranibizumab. And then we have other competing molecules Eylea and Vabysmo and some off-label usage of the cancer drug Avastin. But all in all, a market opportunity of €5 billion, which is growing on the back of an elderly population driving increased need for this kind of drugs. And also, to some extent, more cost-efficient options coming to the market within the ranibizumab or Lucentis biosimilars, with a particular focus now on Ximluci and its performance last quarter. Important to note is that we have a constant cash profit sharing coming in in Q1 2026 in relation to fourth quarter of 2025. So we'll see a little bit later in the presentation, when Jane goes through the cash flow, that we had 13 million Swedish crowns coming in as cash this quarter. And that was from the fourth quarter. And we'll have a similar amount as a result of sales this quarter. But the volumes have gone down slightly compared to last quarter. But it's a result of a focus on maintaining profit margin level and maintaining the profit contribution in a market where we actually are seeing prices going down and a quite high degree of price competitiveness within this market segment. And we are, as we've talked about before, going through several measures to reduce our production cost. And we believe that that is going to bear fruit in 2027 and onwards. And our estimation is that that can unlock further volume growth for us, but for now, we are going to have to focus on maintaining the profit margin with the current production cost that we have. We still have an inventory of mainly drug substance, which we are now gradually converting into cash as we are shipping more product to our partner STADA, and that will take place during the course of this year and next year. So it's 170 million Swedish crowns, which we expect to gradually be converted into cash. Then US, we released a press release last week; we resubmitted the BLA to FDA. As you might recall, we had a Complete Response Letter in October last year, and that was due to one of our contract manufacturers having unresolved observations from an inspection performed by the FDA during last year. And that site has now worked through those observations and has submitted the documentation to the FDA, where all the actions in relation to the observations have been finalized and the related documentation submitted to the FDA. So, we now expect a regulatory timeline of six months. And we'll have to wait and see whether FDA chooses to reinspect this specific site or not. And we'll have to get back when we know the specific decision date from the FDA. And the activities leading up to that decision are underway. Then, shifting gears to Xdivane®, an Opdivo® biosimilar candidate, we're quite excited about this program actually. It is going according to plan towards regulatory submission to the US FDA in the second half of 2027 to enable an approval in the second half of 2028 and an ability to launch the product in early 2029, provided, of course, a timely approval. And that is the point in time when the patent on Opdivo expires. It's an ongoing clinical trial. Recruitment is going according to plan. And we're also in parallel going through all related CMC activities, specifically process characterization and validation of both drug substance and drug product processes, which is also worth mentioning. We are working with a well-established contract manufacturer for this program with a long history of supplying commercial pharmaceutical products to the US and having successfully gone through FDA inspections for related products. So we feel quite comfortable in that we have reduced that development risk, if you will, having learned quite a bit from our Ximluci program. In relation to financing of the development activities. We released a press release this morning where we have agreed with our partner Intas in relation to financing on specific CMC related activities which are under Xbrane responsibility and were, under the original license agreement, Xbrane's financing responsibility. Now, Intas has agreed to partly finance these activities, and that will take place during the course of this and next year and will accrue with an 18% annual add-on on these respective expenses they are paying for. And then, when we are entitled to profit sharing once the product is on the market, those expenses will be deducted prior to Xbrane receiving any profit sharing in connection with this. Intas has also been granted an option to make a one-time lump sum payment corresponding to 40 months of forecasted profit sharing, and they can do that at any point in time during the course of the license. And if they were to do so, that would then release them from the obligation of paying Xbrane any further profit sharing from sales of the product. However, we do have a period from this point and six months ahead where, if we were to be able to arrange other suitable financing, we could essentially repay whatever Intas would have paid at that point in time and then reverse this option to make the one-time lump sum payment. So that's the essence of this arrangement. And in connection with this, we also engaged a company called Venture Valuation AG, an expert in valuing pharmaceutical products. And they had a look on the prospects of Xdivane. They, under the fundamental assumption that the product is approved and could be launched beginning of 2029 in the US and upon European patent expiration mid-2030. They made what they thought were reasonable assumptions with regard to overall market opportunity, biosimilar volume penetration, price discounts and market share of Xdivane. Looking at how oncology biosimilars have developed historically in the US, the level of expected competition for this specific molecule, and so on and so forth. And then applying the profit sharing levels, which Xbrane is entitled to from this program. And, um, and came to, uh, let's call it the base case, um, with over the course of ten years from 29 to 20, 38, accumulated profit sharing of close to 10 billion Swedish crowns, out of which, um, a third, uh, would be related to first four years. And if you take that expected profit sharing during the course of these four years and calculate a net present value at the beginning of 29 using a 15% discount rate, you end up at 4.4 billion Swedish crowns. So we did this valuation in connection with this amendment, which was done with Intas. And it's to give some kind of guidance. guidance on what 40 months of profit sharing could be worth should that one-time lump sum payment option be exercised by Intas as I described on the last slide. So I think that was the essence from an operational perspective. And we can then shift over to the financials. So I hand over to Jane.

Jane
12:30 - 14:54

Yes. And so the revenue for the period amounted to 17.3 million Swedish crowns, whereof 17.2 related to product sales of Ximluci to STADA. And the gross profit margin amounted to 39%. During these coming quarters, we expect more product sales as we have production slots planned, and we have also started the production on-site during these next coming quarters. The administration expenses amounted to 17.6 million Swedish crowns, and R&D expenses amounted to 9.9 million Swedish crowns, whereof 2.7 million relates to the amortization of intangible assets, both of which are in line with our expected expenses. The administration expenses amounted to 17.6 million Swedish crowns, and R&D expenses amounted to 9.9 million Swedish crowns, whereof 2.7 million related to amortization of intangible assets, both of which are in line with our expected expenses. This is the breakdown of the cash flow. You have seen this before, and as you can see, we received 13 million Swedish crowns of the profit sharing from STADA related to Q4 2025, and the production of finished goods, which will be shipped during the second quarter, amounted to 4 million Swedish crowns, and the fixed costs of admin and R&D, as explained on the last slide, amounted to 17 million Swedish crowns, and some small investments have been made on Ximluci. Among other things, to reduce the COGS, as explained, and also some expenses have been invested into the Xdivane project. The closing balance of cash was 66.7 million at the end of the quarter. Here you can see the operating cash flow, which amounted to 8.5 million Swedish crowns in Q1. And as I mentioned, the cash amounted to 66.7 million Swedish crowns at the end of March 2026.

Martin
15:00 - 16:08

So the key takeaways from the quarter: Ximluci is launched in 24 countries. We have constant market share of 8% from a volume perspective in Europe. We are working on several initiatives to bring down the production cost of Ximluci. That's really the most important thing for that program right now. And it's really to ensure the long-term competitiveness of the program in the market, where we are seeing reduced price levels overall. We have resubmitted the BLA to the US FDA, and we expect a six-month regulatory process. So we hope for a decision date and of course, an approval during the second half of this year. And Xdivane development is proceeding according to plan and we are targeting BLA submission second half of 2027. So with that said, I think we are shifting over to questions and we start with any potential questions from people calling in.

Operator
16:10 - 16:21

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad.

Martin
16:40 - 17:57

There seems to be no questions from people calling in. We have one question in the chat here. How likely is it that Intas will use the 40-month option? Regarding the timing, it is truly impossible to answer that question; we cannot estimate the likelihood of Intas choosing to exercise this option or when it would occur. It would depend on multiple different factors, such as timing of approval and the level of competitiveness at that point in time and how the market has developed up until then. So it's really impossible for us to estimate that likelihood. So, I think that was the only question on the chat. So, with that said, we will then close the call, and we are here and available over email or phone should there be any other questions, and otherwise, we are looking forward to our next quarterly update, and have a great day, all of you. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…